The stock of Mesoblast Limited (NASDAQ:MESO) decreased by $0.0 on Friday to finish at $1.25, down 0.00 percent. The last five days have seen an average of 1,079,560 shares of common stock traded. 21 times new highs were reached in the current year, with a fall of -$1.6600. The average number of shares traded over the last 20 days was 983,650, while the average volume over the last 50 days totaled 505,212.
MESO stock dropped -69.40% since last month. On 08/11/23, the company’s shares reached a one-month low of $1.1552. The stock touched a high of $5.12 on 07/17/23, after rallying from a low of $1.19 in 52 weeks. The price of MESO stock has declined by -57.04% or -$1.6600 this year, reaching a new high 21 times. Still, the stock price is down -75.59% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Valuation Metrics
Beta for the stock is 3.36. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 25.21, the price-to-book (PB) ratio of 0.38.
Financial Health
For the three months ended March 30, Mesoblast Limited’s quick ratio was 1.10, while its current ratio was 1.10, indicating its ability to pay off its debt. The company’s long-term debt to equity ratio for the quarter ending March 30 is 0.22, and the total debt to equity ratio is 0.24. Based on annual data, it had gross profit of -$20.54 million and revenue of $10.21 million.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. MESO’s return on assets (ROA) during the last 12 months has been -12.20%. There was a -12.20% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was -16.30%.
Earnings Surprise
According to Mesoblast Limited’s quarterly financial report for the quarter that ended March 30. A lower net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $10.21 million, while revenues rose by 26.93% to $0.0. It was predicted that Mesoblast Limited’s quarterly earnings would be -$0.13, but it ended up being -$0.17, beating the consensus by 23.50%. EBITDA was -$12.67 million for the quarter. At the end of Mesoblast Limited’s most recent quarter ended March 30, its liabilities totaled 168.27 million, while its total debt was $114.61 million.
Technical Picture
Here’s a quick look at Mesoblast Limited’s (MESO) price momentum from a technical perspective. As of 11 August, the RSI 9-day stood at 10.47%, suggesting the stock is oversold, with a 418.30% historical volatility rate.
The stochastic %K and %D were 1.74% and 1.74% respectively, while the average true range (ATR) was 0.3660. Based on the 14-day stochastic reading of 2.54%, the RSI (14) reading is 16.65%. On the 9-day MACD Oscillator, the stock is at -0.9944, and the 14-day reading is at -1.7338.
Analyst Ratings
Mesoblast Limited (NASDAQ: MESO) was downgraded by Maxim Group to a a Hold rating in its latest research report. The stock was previously rated as a a Buy. Analysts have assigned Mesoblast Limited (MESO) an Hold rating. MESO is a stock that is recommended for selling by 1 brokerage firm, while 5 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 0 rates it overweight and 1 other recommend it as a buy.
What is MESO’s price target for the next 12 months?
The current consensus forecast for the stock is between $1.50 and $23.00, with a median target price of $2.47. In analyzing these forecasts, the average price target given by analysts for Mesoblast Limited (MESO) is $6.90.
